2025 Q4 -tulosraportti
Vain PDF
33 päivää sitten
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 10 | - | - | ||
| 100 | - | - | ||
| 174 | - | - | ||
| 1 546 | - | - | ||
| 693 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·39 min sittenI don't know much about technical analysis, and have previously dismissed it a bit. But based on the little I know, isn't it still a bullish chart? Based only on the price structure, that is. I understand this is biotech, that is, but this could be the new, higher bottom and we might get a breakout tomorrow or the day after tomorrow. Anyone want to comment?
·30 min sittenWhy this completely changes the commercial game 4 This is why the data Circio presented in Boston (ASGCT) shook the industry (40x expression in heart, 50x in eye, and 22x output at 10x LOWER DOSE than standard linear vectors). By allowing the cell to continuously produce its own circular RNA from within, the circVec platform solves the three biggest problems in the gene therapy industry at once: 1. Extreme durability and longevity (circular RNA is not broken down by the cell's defense systems like regular linear mRNA). 2. Minimal toxicity (since one can use a 10 times lower dose to get the same or better effect, one avoids the side effects of high dosing). 3. Unmatched scalability (one produces a standard vector, not complex, synthetic RNA molecules in a factory). While inexperienced investors here at home stare intently at the daily chart and stress over 10 % technical warrant noise, the global biotech community is looking at who actually has the most viable architecture for the future. The US giants have the money, but Circio owns the smart biological architecture that Big Pharma desperately needs to make their gene therapies safe and effective. VECTOR TECHNOLOGY IS THE FUTURE. WE KNOW WHAT WE OWN! 🚀
·50 min sittenDon't quite understand why the subscription rights aren't more popular now. You can play it reasonably safe for three weeks by exchanging some shares for subscription rights. Just as an example: Let's say you have 100k shares, sell 50k and buy 50k subscription rights. Then you can assess what is most profitable later. If the share goes down 3 kr, you drop the subscription rights with a discount and instead buy back the shares you sold plus more for the price you received. Or use the profit for other things. Then it costs you about 60øre to get back 3 kr. If the share goes up, you use the subscription rights with a discount and have profited from it. The only thing that can ruin that theory is a massive price increase towards Friday, as I see it.
·55 min sitten · MuokattuA small plea to my fellow shareholders: STAY in the boat tomorrow. Shorters will be ready to profit from sellers' uncertainty and make the stock swing as we saw today. The case is strong, trust the gut feeling you had when you bought in - EVEN if it was at a price of 12-14 - We have only just begun.·29 min sittenWhy this completely changes the commercial game 4 This is why the data Circio presented in Boston (ASGCT) shook the industry (40x expression in heart, 50x in eye, and 22x output at 10x LOWER DOSE than standard linear vectors). By allowing the cell to continuously produce its own circular RNA from within, the circVec platform solves the three biggest problems in the gene therapy industry at once: 1. Extreme durability and longevity (circular RNA is not broken down by the cell's defense systems like regular linear mRNA). 2. Minimal toxicity (since one can use a 10 times lower dose to get the same or better effect, one avoids the side effects of high dosing). 3. Unmatched scalability (one produces a standard vector, not complex, synthetic RNA molecules in a factory). While inexperienced investors here at home stare intently at the daily chart and stress over 10 % technical warrant noise, the global biotech community is looking at who actually has the most viable architecture for the future. The US giants have the money, but Circio owns the smart biological architecture that Big Pharma desperately needs to make their gene therapies safe and effective. VECTOR TECHNOLOGY IS THE FUTURE. WE KNOW WHAT WE OWN! 🚀
·1 t sittenOur friend says: Johnson & Johnson (J&J) can absolutely be a relevant partner, and they actually already have an indirect connection to Circio. Large pharmaceutical companies like J&J (through its subsidiary Janssen) are completely dependent on partnerships with smaller biotech companies to fill their research pipelines with innovative technology. Existing connection between Circio and J&J Combination study in the USA: Circio already has a clinical phase 2 study underway in the USA (led by Georgetown University) for its cancer vaccine TG01. In this study, TG01 is tested in combination with the cancer drug daratumumab, which was developed by Janssen (J&J), in addition to a drug from BMS. Strategy for "Big Pharma" deals: The company's stated strategy is to enter into licensing and technology agreements with large players ("Big Pharma") to roll out its circVec platform. They recently signed a research and development agreement with a currently unofficial "Big Pharma" company. Why J&J is a logical partner Focus on oncology and targeted therapy: J&J has one of the world's largest oncology departments. They have strongly stated that they want to replace traditional chemotherapy with targeted therapies – something Circio's immunotherapies and RNA technology fall directly under. Financial muscle: J&J has the capital required to fund large, costly phase 2 and phase 3 studies, something a smaller company on Oslo Børs is completely dependent on to bring the medicine to market.·1 t sittenWhy this completely changes the commercial game 4 This is why the data Circio presented in Boston (ASGCT) shook the industry (40x expression in heart, 50x in eye, and 22x output at 10x LOWER DOSE than standard linear vectors). By letting the cell continuously produce its own circular RNA from within, the circVec platform solves the three biggest problems in the gene therapy industry at once: 1. Extreme durability and longevity (circular RNA is not broken down by the cell's defense systems like regular linear mRNA). 2. Minimal toxicity (since one can use a 10 times lower dose to get the same or better effect, one avoids the side effects of high dosing). 3. Unrivaled scalability (one produces a standard vector, not complex, synthetic RNA molecules in a factory). While inexperienced investors at home stare intently at the daily chart and stress over 10 % technical warrant noise, the global biotech community is watching who actually has the most viable architecture for the future. The US giants have the money, but Circio owns the smart biological architecture that Big Pharma desperately needs to make its gene therapies safe and effective. VECTOR TECHNOLOGY IS THE FUTURE. WE KNOW WHAT WE OWN!
·1 t sitten:-) With all positive info out now, one must surely say that the short sellers are overly bold. If we believe what appears in the links below and what we have heard before from the company, sit tight. As felipecr comments below here, rather buy more now.·1 t sittenWhy this completely changes the commercial game 4 This is why the data Circio presented in Boston (ASGCT) shook the industry (40x expression in heart, 50x in eye, and 22x output at 10x LOWER DOSE than standard linear vectors). By letting the cell continuously produce its own circular RNA from within, the circVec platform solves the three biggest problems in the gene therapy industry at once: 1. Extreme durability and longevity (circular RNA is not broken down by the cell's defense systems like regular linear mRNA). 2. Minimal toxicity (since one can use a 10 times lower dose to get the same or better effect, one avoids the side effects of high dosing). 3. Unrivaled scalability (one produces a standard vector, not complex, synthetic RNA molecules in a factory). While inexperienced investors at home stare intently at the daily chart and stress over 10 % technical warrant noise, the global biotech community is watching who actually has the most viable architecture for the future. The US giants have the money, but Circio owns the smart biological architecture that Big Pharma desperately needs to make its gene therapies safe and effective. VECTOR TECHNOLOGY IS THE FUTURE. WE KNOW WHAT WE OWN!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
33 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·39 min sittenI don't know much about technical analysis, and have previously dismissed it a bit. But based on the little I know, isn't it still a bullish chart? Based only on the price structure, that is. I understand this is biotech, that is, but this could be the new, higher bottom and we might get a breakout tomorrow or the day after tomorrow. Anyone want to comment?·30 min sittenWhy this completely changes the commercial game 4 This is why the data Circio presented in Boston (ASGCT) shook the industry (40x expression in heart, 50x in eye, and 22x output at 10x LOWER DOSE than standard linear vectors). By allowing the cell to continuously produce its own circular RNA from within, the circVec platform solves the three biggest problems in the gene therapy industry at once: 1. Extreme durability and longevity (circular RNA is not broken down by the cell's defense systems like regular linear mRNA). 2. Minimal toxicity (since one can use a 10 times lower dose to get the same or better effect, one avoids the side effects of high dosing). 3. Unmatched scalability (one produces a standard vector, not complex, synthetic RNA molecules in a factory). While inexperienced investors here at home stare intently at the daily chart and stress over 10 % technical warrant noise, the global biotech community is looking at who actually has the most viable architecture for the future. The US giants have the money, but Circio owns the smart biological architecture that Big Pharma desperately needs to make their gene therapies safe and effective. VECTOR TECHNOLOGY IS THE FUTURE. WE KNOW WHAT WE OWN! 🚀
- ·50 min sittenDon't quite understand why the subscription rights aren't more popular now. You can play it reasonably safe for three weeks by exchanging some shares for subscription rights. Just as an example: Let's say you have 100k shares, sell 50k and buy 50k subscription rights. Then you can assess what is most profitable later. If the share goes down 3 kr, you drop the subscription rights with a discount and instead buy back the shares you sold plus more for the price you received. Or use the profit for other things. Then it costs you about 60øre to get back 3 kr. If the share goes up, you use the subscription rights with a discount and have profited from it. The only thing that can ruin that theory is a massive price increase towards Friday, as I see it.
- ·55 min sitten · MuokattuA small plea to my fellow shareholders: STAY in the boat tomorrow. Shorters will be ready to profit from sellers' uncertainty and make the stock swing as we saw today. The case is strong, trust the gut feeling you had when you bought in - EVEN if it was at a price of 12-14 - We have only just begun.·29 min sittenWhy this completely changes the commercial game 4 This is why the data Circio presented in Boston (ASGCT) shook the industry (40x expression in heart, 50x in eye, and 22x output at 10x LOWER DOSE than standard linear vectors). By allowing the cell to continuously produce its own circular RNA from within, the circVec platform solves the three biggest problems in the gene therapy industry at once: 1. Extreme durability and longevity (circular RNA is not broken down by the cell's defense systems like regular linear mRNA). 2. Minimal toxicity (since one can use a 10 times lower dose to get the same or better effect, one avoids the side effects of high dosing). 3. Unmatched scalability (one produces a standard vector, not complex, synthetic RNA molecules in a factory). While inexperienced investors here at home stare intently at the daily chart and stress over 10 % technical warrant noise, the global biotech community is looking at who actually has the most viable architecture for the future. The US giants have the money, but Circio owns the smart biological architecture that Big Pharma desperately needs to make their gene therapies safe and effective. VECTOR TECHNOLOGY IS THE FUTURE. WE KNOW WHAT WE OWN! 🚀
- ·1 t sittenOur friend says: Johnson & Johnson (J&J) can absolutely be a relevant partner, and they actually already have an indirect connection to Circio. Large pharmaceutical companies like J&J (through its subsidiary Janssen) are completely dependent on partnerships with smaller biotech companies to fill their research pipelines with innovative technology. Existing connection between Circio and J&J Combination study in the USA: Circio already has a clinical phase 2 study underway in the USA (led by Georgetown University) for its cancer vaccine TG01. In this study, TG01 is tested in combination with the cancer drug daratumumab, which was developed by Janssen (J&J), in addition to a drug from BMS. Strategy for "Big Pharma" deals: The company's stated strategy is to enter into licensing and technology agreements with large players ("Big Pharma") to roll out its circVec platform. They recently signed a research and development agreement with a currently unofficial "Big Pharma" company. Why J&J is a logical partner Focus on oncology and targeted therapy: J&J has one of the world's largest oncology departments. They have strongly stated that they want to replace traditional chemotherapy with targeted therapies – something Circio's immunotherapies and RNA technology fall directly under. Financial muscle: J&J has the capital required to fund large, costly phase 2 and phase 3 studies, something a smaller company on Oslo Børs is completely dependent on to bring the medicine to market.·1 t sittenWhy this completely changes the commercial game 4 This is why the data Circio presented in Boston (ASGCT) shook the industry (40x expression in heart, 50x in eye, and 22x output at 10x LOWER DOSE than standard linear vectors). By letting the cell continuously produce its own circular RNA from within, the circVec platform solves the three biggest problems in the gene therapy industry at once: 1. Extreme durability and longevity (circular RNA is not broken down by the cell's defense systems like regular linear mRNA). 2. Minimal toxicity (since one can use a 10 times lower dose to get the same or better effect, one avoids the side effects of high dosing). 3. Unrivaled scalability (one produces a standard vector, not complex, synthetic RNA molecules in a factory). While inexperienced investors at home stare intently at the daily chart and stress over 10 % technical warrant noise, the global biotech community is watching who actually has the most viable architecture for the future. The US giants have the money, but Circio owns the smart biological architecture that Big Pharma desperately needs to make its gene therapies safe and effective. VECTOR TECHNOLOGY IS THE FUTURE. WE KNOW WHAT WE OWN!
- ·1 t sitten:-) With all positive info out now, one must surely say that the short sellers are overly bold. If we believe what appears in the links below and what we have heard before from the company, sit tight. As felipecr comments below here, rather buy more now.·1 t sittenWhy this completely changes the commercial game 4 This is why the data Circio presented in Boston (ASGCT) shook the industry (40x expression in heart, 50x in eye, and 22x output at 10x LOWER DOSE than standard linear vectors). By letting the cell continuously produce its own circular RNA from within, the circVec platform solves the three biggest problems in the gene therapy industry at once: 1. Extreme durability and longevity (circular RNA is not broken down by the cell's defense systems like regular linear mRNA). 2. Minimal toxicity (since one can use a 10 times lower dose to get the same or better effect, one avoids the side effects of high dosing). 3. Unrivaled scalability (one produces a standard vector, not complex, synthetic RNA molecules in a factory). While inexperienced investors at home stare intently at the daily chart and stress over 10 % technical warrant noise, the global biotech community is watching who actually has the most viable architecture for the future. The US giants have the money, but Circio owns the smart biological architecture that Big Pharma desperately needs to make its gene therapies safe and effective. VECTOR TECHNOLOGY IS THE FUTURE. WE KNOW WHAT WE OWN!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 10 | - | - | ||
| 100 | - | - | ||
| 174 | - | - | ||
| 1 546 | - | - | ||
| 693 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
33 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·39 min sittenI don't know much about technical analysis, and have previously dismissed it a bit. But based on the little I know, isn't it still a bullish chart? Based only on the price structure, that is. I understand this is biotech, that is, but this could be the new, higher bottom and we might get a breakout tomorrow or the day after tomorrow. Anyone want to comment?·30 min sittenWhy this completely changes the commercial game 4 This is why the data Circio presented in Boston (ASGCT) shook the industry (40x expression in heart, 50x in eye, and 22x output at 10x LOWER DOSE than standard linear vectors). By allowing the cell to continuously produce its own circular RNA from within, the circVec platform solves the three biggest problems in the gene therapy industry at once: 1. Extreme durability and longevity (circular RNA is not broken down by the cell's defense systems like regular linear mRNA). 2. Minimal toxicity (since one can use a 10 times lower dose to get the same or better effect, one avoids the side effects of high dosing). 3. Unmatched scalability (one produces a standard vector, not complex, synthetic RNA molecules in a factory). While inexperienced investors here at home stare intently at the daily chart and stress over 10 % technical warrant noise, the global biotech community is looking at who actually has the most viable architecture for the future. The US giants have the money, but Circio owns the smart biological architecture that Big Pharma desperately needs to make their gene therapies safe and effective. VECTOR TECHNOLOGY IS THE FUTURE. WE KNOW WHAT WE OWN! 🚀
- ·50 min sittenDon't quite understand why the subscription rights aren't more popular now. You can play it reasonably safe for three weeks by exchanging some shares for subscription rights. Just as an example: Let's say you have 100k shares, sell 50k and buy 50k subscription rights. Then you can assess what is most profitable later. If the share goes down 3 kr, you drop the subscription rights with a discount and instead buy back the shares you sold plus more for the price you received. Or use the profit for other things. Then it costs you about 60øre to get back 3 kr. If the share goes up, you use the subscription rights with a discount and have profited from it. The only thing that can ruin that theory is a massive price increase towards Friday, as I see it.
- ·55 min sitten · MuokattuA small plea to my fellow shareholders: STAY in the boat tomorrow. Shorters will be ready to profit from sellers' uncertainty and make the stock swing as we saw today. The case is strong, trust the gut feeling you had when you bought in - EVEN if it was at a price of 12-14 - We have only just begun.·29 min sittenWhy this completely changes the commercial game 4 This is why the data Circio presented in Boston (ASGCT) shook the industry (40x expression in heart, 50x in eye, and 22x output at 10x LOWER DOSE than standard linear vectors). By allowing the cell to continuously produce its own circular RNA from within, the circVec platform solves the three biggest problems in the gene therapy industry at once: 1. Extreme durability and longevity (circular RNA is not broken down by the cell's defense systems like regular linear mRNA). 2. Minimal toxicity (since one can use a 10 times lower dose to get the same or better effect, one avoids the side effects of high dosing). 3. Unmatched scalability (one produces a standard vector, not complex, synthetic RNA molecules in a factory). While inexperienced investors here at home stare intently at the daily chart and stress over 10 % technical warrant noise, the global biotech community is looking at who actually has the most viable architecture for the future. The US giants have the money, but Circio owns the smart biological architecture that Big Pharma desperately needs to make their gene therapies safe and effective. VECTOR TECHNOLOGY IS THE FUTURE. WE KNOW WHAT WE OWN! 🚀
- ·1 t sittenOur friend says: Johnson & Johnson (J&J) can absolutely be a relevant partner, and they actually already have an indirect connection to Circio. Large pharmaceutical companies like J&J (through its subsidiary Janssen) are completely dependent on partnerships with smaller biotech companies to fill their research pipelines with innovative technology. Existing connection between Circio and J&J Combination study in the USA: Circio already has a clinical phase 2 study underway in the USA (led by Georgetown University) for its cancer vaccine TG01. In this study, TG01 is tested in combination with the cancer drug daratumumab, which was developed by Janssen (J&J), in addition to a drug from BMS. Strategy for "Big Pharma" deals: The company's stated strategy is to enter into licensing and technology agreements with large players ("Big Pharma") to roll out its circVec platform. They recently signed a research and development agreement with a currently unofficial "Big Pharma" company. Why J&J is a logical partner Focus on oncology and targeted therapy: J&J has one of the world's largest oncology departments. They have strongly stated that they want to replace traditional chemotherapy with targeted therapies – something Circio's immunotherapies and RNA technology fall directly under. Financial muscle: J&J has the capital required to fund large, costly phase 2 and phase 3 studies, something a smaller company on Oslo Børs is completely dependent on to bring the medicine to market.·1 t sittenWhy this completely changes the commercial game 4 This is why the data Circio presented in Boston (ASGCT) shook the industry (40x expression in heart, 50x in eye, and 22x output at 10x LOWER DOSE than standard linear vectors). By letting the cell continuously produce its own circular RNA from within, the circVec platform solves the three biggest problems in the gene therapy industry at once: 1. Extreme durability and longevity (circular RNA is not broken down by the cell's defense systems like regular linear mRNA). 2. Minimal toxicity (since one can use a 10 times lower dose to get the same or better effect, one avoids the side effects of high dosing). 3. Unrivaled scalability (one produces a standard vector, not complex, synthetic RNA molecules in a factory). While inexperienced investors at home stare intently at the daily chart and stress over 10 % technical warrant noise, the global biotech community is watching who actually has the most viable architecture for the future. The US giants have the money, but Circio owns the smart biological architecture that Big Pharma desperately needs to make its gene therapies safe and effective. VECTOR TECHNOLOGY IS THE FUTURE. WE KNOW WHAT WE OWN!
- ·1 t sitten:-) With all positive info out now, one must surely say that the short sellers are overly bold. If we believe what appears in the links below and what we have heard before from the company, sit tight. As felipecr comments below here, rather buy more now.·1 t sittenWhy this completely changes the commercial game 4 This is why the data Circio presented in Boston (ASGCT) shook the industry (40x expression in heart, 50x in eye, and 22x output at 10x LOWER DOSE than standard linear vectors). By letting the cell continuously produce its own circular RNA from within, the circVec platform solves the three biggest problems in the gene therapy industry at once: 1. Extreme durability and longevity (circular RNA is not broken down by the cell's defense systems like regular linear mRNA). 2. Minimal toxicity (since one can use a 10 times lower dose to get the same or better effect, one avoids the side effects of high dosing). 3. Unrivaled scalability (one produces a standard vector, not complex, synthetic RNA molecules in a factory). While inexperienced investors at home stare intently at the daily chart and stress over 10 % technical warrant noise, the global biotech community is watching who actually has the most viable architecture for the future. The US giants have the money, but Circio owns the smart biological architecture that Big Pharma desperately needs to make its gene therapies safe and effective. VECTOR TECHNOLOGY IS THE FUTURE. WE KNOW WHAT WE OWN!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 10 | - | - | ||
| 100 | - | - | ||
| 174 | - | - | ||
| 1 546 | - | - | ||
| 693 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt